{"schema_version":"secwatch.filing_event.v1","accession":"0001293971-24-000020","form_type":"8-K","ticker":null,"cik":"0001293971","company_name":"bluebird bio, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.752954+00:00","generated_at":"2026-06-02T05:02:07.674163+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"bluebird bio Q1 net revenue $18.6M; 15 patient starts year-to-date; restates prior financials","bullets":["Q1 2024 net revenue $18.6M vs $2.4M Q1 2023, driven by ZYNTEGLO revenue increase.","15 patient starts in 2024: 11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA; full-year guidance 85-105 starts.","First LYFGENIA patient start completed; revenue expected in Q3 2024.","Cash $264M (incl. $52M restricted); expects runway through Q1 2026 assuming $50M additional loan tranches.","Restating 2022 and 2023 financials for lease accounting; no impact on cash or revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001293971-24-000020","json":"https://secwatch.observer/filing/0001293971-24-000020.json","markdown":"https://secwatch.observer/filing/0001293971-24-000020.md","text":"https://secwatch.observer/filing/0001293971-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/0001293971-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/blue-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:02:07.674163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe7120cbc73401f9a188179e1291782e1ee4f7ef","claim":"bluebird bio, Inc. reported the three months ended March 31, 2024 results: revenue $18.6 million.","evidence_excerpt":"– 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 – – First quarter 2024 net revenue of $18.6 million – – Management to host conference call today, May 9, 2024 at 8:00 am ET – SOMERVILLE, Mass. – May 9, 2024 – bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/0001293971-24-000020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$18.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}